Exponent demonstrates strong demand recovery, with Q2 revenue before reimbursement up 12% to $148.9M and EBITDA margin rising to 28.7%. I see sustainable growth potential, but hiring discipline and ...

“Recursive self-improvement” is the idea that artificial intelligence could learn to build and train itself, creating exponential new progress — and risk. Jeff Clune, a computer scientist and ...

But a new study shows that work use cases make up less of the picture than AI companies claim. AI companies like Anthropic and OpenAI regularly publish reports on how people are using products like ...

AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

Ask a roomful of senior executives what AI can do for their business, and the answers will probably cluster around the same themes: lower costs, smaller headcount, faster processes, leaner operations.

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...